Bio-Rad Laboratories Inc. (BIO) reported $2.59B of revenue for the twelve months ended Sep 30, 2026. That is up 1.4% from the year before. Revenue for fiscal 2025 was $2.58B.

Yes. Bio-Rad Laboratories Inc. earned $1.02B in net income for the twelve months ended Sep 30, 2026, a net margin of 39.5%.

How much cash and debt does BIO have?

Bio-Rad Laboratories Inc. reported $465.30M in cash and cash equivalents and $803.10M of debt on its most recent balance sheet in SEC filings.

How fast is BIO revenue growing?

Bio-Rad Laboratories Inc.'s revenue changed +0.7% in fiscal 2025, to $2.58B. Its compound annual growth rate was +0.3% over 5 years and +2.5% over 10 years.

What is BIO gross margin?

Bio-Rad Laboratories Inc.'s gross profit was $1.33B on $2.59B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 51.3%.

What is BIO free cash flow?

Bio-Rad Laboratories Inc. generated $329.10M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $468.10M less capital expenditures.

What is BIO earnings per share?

Diluted earnings per share were $37.91 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did BIO last report financial results?

The latest statements here come from Bio-Rad Laboratories Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.

Where does this BIO financial data come from?

Quantisnow builds these statements from the structured XBRL data Bio-Rad Laboratories Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · BIO

Bio-Rad Laboratories Inc. (BIO) financials

For the twelve months ended Sep 30, 2026, Bio-Rad Laboratories Inc. reported $2.59B of revenue and $1.02B of net income.

Revenue, TTM: $2.59B
Revenue growth, YoY: +1.4%
Net income, TTM: $1.02B
Net margin: 39.5%
Free cash flow, TTM: $329.10M
EPS, diluted, TTM: $37.91
Cash: $465.30M
Total debt: $803.10M
P/E: 10.21
P/S: 4.03
Market cap: $10.44B

Annual revenue$2.58B

FY2016FY2025

Annual net income$759.90M

FY2016FY2025

Annual free cash flow$374.60M

FY2016FY2025

BIO revenue and earnings growth

BIO revenueQ3 2026$656.40M

Quarter YoY: +0.5%
QoQ: +0.8%
FY YoY: +0.7%
5Y CAGR: +0.3%
10Y CAGR: +2.5%

BIO revenue was $656.40M in fiscal Q3 2026 (ended Sep 30, 2026), up 0.5% from a year earlier and up 0.8% from the prior quarter. For the full fiscal 2025 it was $2.58B, up 0.7% from fiscal 2024. Compound annual growth was +0.3% over 5 years and +2.5% over 10 years. It rose in 7 of the last 10 fiscal years.

BIO net incomeQ3 2026$458.60M

QoQ: +23.5%
5Y CAGR: -27.6%
10Y CAGR: +21.4%

BIO net income was $458.60M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$341.90M a year earlier and up 23.5% from the prior quarter. For the full fiscal 2025 it was $759.90M, compared with -$1.84B in fiscal 2024. Compound annual growth was -27.6% over 5 years and +21.4% over 10 years.

BIO EPSQ3 2026$17.02

QoQ: +22.9%
5Y CAGR: -26.1%
10Y CAGR: +22.3%

BIO diluted EPS was $17.02 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$12.70 a year earlier and up 22.9% from the prior quarter. For the full fiscal 2025 it was $27.85, compared with -$65.36 in fiscal 2024. Compound annual growth was -26.1% over 5 years and +22.3% over 10 years.

BIO free cash flowQ3 2026$65.20M

Quarter YoY: -26.9%
QoQ: -2.2%
FY YoY: +29.4%
5Y CAGR: -4.7%
10Y CAGR: +17.6%

BIO free cash flow was $65.20M in fiscal Q3 2026 (ended Sep 30, 2026), down 26.9% from a year earlier and down 2.2% from the prior quarter. For the full fiscal 2025 it was $374.60M, up 29.4% from fiscal 2024. Compound annual growth was -4.7% over 5 years and +17.6% over 10 years. It rose in 6 of the last 7 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$2.58B	$2.57B	$2.67B	$2.80B	$2.92B	$2.55B	$2.31B	$2.29B	$2.16B	$2.07B
Cost of revenue	$1.24B	$1.19B	$1.24B	$1.23B	$1.28B	$1.11B	$1.05B	$1.07B	$972.45M	$929.74M
Gross profit	$1.34B	$1.38B	$1.43B	$1.57B	$1.64B	$1.44B	$1.26B	$1.22B	$1.19B	$1.14B
Research and development	$275.60M	$295.90M	$247.40M	$256.90M	$260.64M	$217.76M	$202.71M	$199.20M	$250.16M	$205.71M
Selling, general and admin	$844.30M	$814.00M	$841.70M	$827.80M	$877.12M	$798.80M	$824.63M	$834.78M	$806.79M	$814.70M
Operating income	$47.20M	$269.00M	$337.80M	$482.60M	$500.34M	$421.33M	$229.66M	-$103.34M	$119.25M	$55.72M
Interest expense	$49.00M	$48.90M	$49.40M	$38.10M	$1.55M	$21.86M	$23.42M	$23.96M	$23.01M	$23.38M
Pre-tax income	$995.50M	-$2.34B	-$850.10M	-$4.70B	$5.45B	$4.92B	$2.26B	$512.66M	$97.81M	$41.56M
Income tax	$235.60M	-$498.30M	-$212.80M	-$1.08B	$1.19B	$1.10B	$502.41M	$147.04M	-$24.44M	$15.56M
Net income	$759.90M	-$1.84B	-$637.30M	-$3.63B	$4.25B	$3.81B	$1.76B	$365.61M	$122.25M	$26.00M
EPS, basic	$27.87	-$65.36	-$21.82	-$121.79	$142.61	$128.13	$58.93	$12.25	$4.12	$0.88
EPS, diluted	$27.85	-$65.36	-$21.82	-$121.79	$140.83	$126.47	$58.27	$12.10	$4.07	$0.88
Diluted shares	27.3M	28.2M	29.2M	29.8M	30.2M	30.2M	30.2M	30.2M	30.0M	29.6M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$529.80M	$489.80M	$403.80M	$434.50M	$471.10M	$667.12M	$662.65M	$434.16M	$384.98M	$457.17M
Short-term investments	$1.01B	$1.18B	$1.20B	$1.36B	$399.13M	$328.91M	$453.97M	$413.27M	$371.15M	$383.18M
Receivables	$460.60M	$452.50M	$489.00M	$494.64M	$423.54M	$419.42M	$392.67M	$392.44M	$464.85M	$372.35M
Inventory	$740.70M	$760.00M	$780.50M	$719.32M	$572.24M	$622.25M	$554.01M	$583.82M	$594.80M	$524.96M
Current assets	$2.91B	$3.03B	$3.05B	$3.16B	$1.99B	$2.14B	$2.18B	$2.02B	$1.98B	$1.84B
Goodwill	$579.80M	$410.50M	$413.60M	$406.50M	$347.30M	$291.90M	$264.10M	$219.80M	$506.10M	$477.10M
Total assets	$10.58B	$9.36B	$12.30B	$13.50B	$17.80B	$12.97B	$8.01B	$5.61B	$4.27B	$3.85B
Current liabilities	$517.00M	$467.80M	$522.80M	$568.71M	$680.94M	$631.54M	$905.50M	$450.80M	$502.70M	$471.32M
Long-term debt	$1.20B	$1.20B	$1.20B	$1.20B	$10.51M	$12.26M	$13.58M	$438.94M	$434.58M	$434.19M
Total debt	$1.20B	$1.20B	$1.20B	$1.20B	$10.51M	$12.26M	$13.58M	$438.94M	$434.58M	$434.19M
Total liabilities	$3.12B	$2.79B	$3.56B	$3.89B	$4.11B	$3.09B	$2.25B	$1.59B	$1.34B	$1.27B
Shareholders' equity	$7.45B	$6.57B	$8.74B	$9.62B	$13.69B	$9.89B	$5.76B	$4.02B	$2.93B	$2.58B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$532.20M	$455.20M	$374.90M	$194.40M	$669.46M	$584.97M	$457.90M	$285.49M	$104.14M	$216.07M
Capital expenditures	$157.60M	$165.60M	$156.70M	$112.80M	$133.75M	$108.56M	$98.53M	$129.82M	$111.33M	$141.44M
Free cash flow	$374.60M	$289.60M	$218.20M	$81.60M	$535.72M	$476.41M	$359.37M	$155.67M	-$7.20M	$74.63M
Investing cash flow	-$189.70M	-$160.20M	$20.20M	-$1.21B	-$797.38M	-$69.89M	-$208.89M	-$186.98M	-$175.57M	-$213.88M
Financing cash flow	-$283.20M	-$218.80M	-$425.60M	$973.60M	-$55.43M	-$523.04M	-$22.76M	-$48.68M	$341.0K	$9.02M
Share repurchases	$295.50M	$203.60M	$428.70M	$215.70M	$50.00M	$100.00M	$28.00M	$48.91M	$2.92M	$0
Stock-based compensation	$58.00M	$62.30M	$61.30M	$60.90M	$51.20M	$41.60M	$35.60M	$27.80M	$23.40M	$19.70M
Depreciation and amortization	$165.40M	$151.60M	$145.90M	$137.30M	$137.60M	$138.60M	$134.20M	$138.10M	$148.70M	$142.90M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	0.7%	-3.9%	-4.7%	-4.1%	14.8%	10.1%	1.0%	6.0%	4.4%	2.4%
Net income growth, YoY	-	-	-	-	11.5%	116.9%	381.0%	199.1%	370.2%	-76.2%
EPS growth, YoY	-	-	-	-	11.4%	117.0%	381.6%	197.3%	362.5%	-76.3%
Gross margin	51.9%	53.7%	53.4%	55.9%	56.1%	56.5%	54.4%	53.4%	55.0%	55.0%
Operating margin	1.8%	10.5%	12.6%	17.2%	17.1%	16.6%	9.9%	-4.5%	5.5%	2.7%
Net margin	29.4%	-71.9%	-23.9%	-129.5%	145.6%	149.8%	76.1%	16.0%	5.7%	1.3%
Free cash flow margin	14.5%	11.3%	8.2%	2.9%	18.3%	18.7%	15.5%	6.8%	-0.3%	3.6%
Return on equity	10.2%	-28.1%	-7.3%	-37.7%	31.1%	38.6%	30.5%	9.1%	4.2%	1.0%
Return on assets	7.2%	-19.7%	-5.2%	-26.9%	23.9%	29.4%	22.0%	6.5%	2.9%	0.7%
Current ratio	5.62	6.48	5.83	5.55	2.92	3.39	2.41	4.49	3.93	3.91
Debt to equity	0.16	0.18	0.14	0.12	0.00	0.00	0.00	0.11	0.15	0.17

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Revenue	$656.40M	$651.00M	$592.10M	$693.20M	$653.00M	$651.60M	$585.40M	$667.50M	$649.70M	$638.50M	$610.80M	$681.20M
Cost of revenue	$327.80M	$305.20M	$282.70M	$348.00M	$309.60M	$306.30M	$279.40M	$325.60M	$293.80M	$283.40M	$284.90M	$314.81M
Gross profit	$328.60M	$345.80M	$309.40M	$345.20M	$343.40M	$345.30M	$306.00M	$342.00M	$355.90M	$355.10M	$325.90M	$366.30M
Research and development	$71.40M	$61.20M	$62.90M	$70.30M	$71.30M	$60.50M	$73.50M	$79.60M	$91.00M	$58.90M	$66.40M	$63.87M
Selling, general and admin	$257.10M	$212.00M	$212.40M	$221.00M	$206.80M	$207.70M	$208.80M	$204.00M	$200.40M	$194.70M	$214.90M	$207.12M
Operating income	-$49.70M	$72.60M	$34.10M	-$118.90M	$65.30M	$77.10M	$23.70M	$58.30M	$64.50M	$101.50M	$44.60M	$95.32M
Interest expense	$12.30M	$12.10M	$12.30M	$12.10M	$12.30M	$12.60M	$12.00M	$12.20M	$12.10M	$12.30M	$12.30M	$12.32M
Pre-tax income	$538.70M	$542.10M	-$689.80M	$929.20M	-$431.10M	$414.00M	$83.40M	-$908.90M	$861.60M	-$2.79B	$491.10M	$428.40M
Income tax	$80.10M	$170.70M	-$162.70M	$209.20M	-$89.20M	$96.20M	$19.40M	-$193.10M	$208.40M	-$620.80M	$107.20M	$78.66M
Net income	$458.60M	$371.40M	-$527.10M	$720.00M	-$341.90M	$317.80M	$64.00M	-$715.80M	$653.20M	-$2.17B	$383.90M	$349.70M
EPS, basic	$17.13	$13.89	-$19.55	$26.61	-$12.70	$11.67	$2.29	-$25.57	$23.37	-$76.26	$13.46	$12.15
EPS, diluted	$17.02	$13.85	-$19.55	$26.59	-$12.70	$11.67	$2.29	-$25.57	$23.34	-$76.26	$13.45	$12.14
Diluted shares	26.9M	26.8M	27.0M	-	26.9M	27.2M	28.0M	-	28.0M	28.4M	28.5M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Cash and equivalents	$465.30M	$517.00M	$507.20M	$529.80M	$395.80M	$369.30M	$521.40M	$489.80M	$410.40M	$406.90M	$433.30M	$403.80M
Short-term investments	$1.20B	$1.10B	$1.06B	$1.01B	$1.02B	$1.00B	$1.14B	$1.18B	$1.21B	$1.21B	$1.21B	$1.20B
Receivables	$422.60M	$441.80M	$426.20M	$460.60M	$464.70M	$469.90M	$424.70M	$452.50M	$461.94M	$445.51M	$444.81M	$489.00M
Inventory	$783.90M	$780.60M	$770.50M	$740.70M	$783.20M	$798.80M	$790.10M	$760.00M	$804.28M	$803.69M	$783.37M	$780.50M
Current assets	$3.08B	$3.02B	$2.94B	$2.91B	$2.84B	$2.81B	$3.04B	$3.03B	$3.06B	$3.06B	$3.06B	$3.05B
Goodwill	$573.00M	$574.30M	$577.10M	$579.80M	$578.70M	$581.60M	$414.60M	$410.50M	$415.10M	$412.12M	$412.82M	$413.60M
Total assets	$10.78B	$10.25B	$9.79B	$10.58B	$9.70B	$10.21B	$9.53B	$9.36B	$10.60B	$9.69B	$12.61B	$12.30B
Current liabilities	$969.10M	$961.30M	$917.00M	$517.00M	$522.30M	$548.90M	$506.60M	$467.80M	$497.94M	$486.96M	$466.15M	$522.80M
Long-term debt	$803.10M	$803.00M	$802.90M	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B
Total debt	$803.10M	$803.00M	$802.90M	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B	$1.20B
Total liabilities	$3.18B	$3.08B	$2.94B	$3.12B	$2.96B	$3.09B	$2.85B	$2.79B	$3.12B	$2.91B	$3.56B	$3.56B
Shareholders' equity	$7.60B	$7.17B	$6.85B	$7.45B	$6.74B	$7.13B	$6.68B	$6.57B	$7.49B	$6.78B	$9.05B	$8.74B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Operating cash flow	$96.40M	$98.70M	$108.10M	$164.90M	$120.90M	$116.50M	$129.90M	$124.20M	$163.60M	$97.60M	$69.80M	$81.00M
Capital expenditures	$31.20M	$32.00M	$30.00M	$45.80M	$31.70M	$45.70M	$34.40M	$42.90M	$40.20M	$42.30M	$40.20M	$42.27M
Free cash flow	$65.20M	$66.70M	$78.10M	$119.10M	$89.20M	$70.80M	$95.50M	$81.30M	$123.40M	$55.30M	$29.60M	$38.74M
Investing cash flow	-$145.90M	-$66.70M	-$93.20M	-$34.20M	-$43.00M	-$115.40M	$2.90M	-$30.50M	-$55.70M	-$30.90M	-$43.10M	$72.19M
Financing cash flow	-$1.60M	-$27.60M	-$44.00M	$3.30M	-$52.50M	-$136.30M	-$97.70M	-$26.20M	-$96.00M	-$96.60M	$0	-$200.57M
Share repurchases	$0	$31.50M	$47.80M	$0	$53.40M	$140.20M	$101.90M	$0	$97.90M	$101.00M	$4.70M	$199.97M
Stock-based compensation	$15.50M	$14.50M	$15.00M	$15.90M	$14.90M	$11.90M	$15.30M	$16.40M	$15.60M	$15.00M	$15.30M	$16.20M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Revenue growth, YoY	0.5%	-0.1%	1.1%	3.9%	0.5%	2.1%	-4.2%	-2.0%	2.8%	-6.3%	-9.8%	-6.7%
Net income growth, YoY	-	16.9%	-	-	-	-	-83.3%	-	514.5%	-	456.4%	-57.8%
EPS growth, YoY	-	18.7%	-	-	-	-	-83.0%	-	541.2%	-	479.7%	-56.3%
Gross margin	50.1%	53.1%	52.3%	49.8%	52.6%	53.0%	52.3%	51.2%	54.8%	55.6%	53.4%	53.8%
Operating margin	-7.6%	11.2%	5.8%	-17.2%	10.0%	11.8%	4.0%	8.7%	9.9%	15.9%	7.3%	14.0%
Net margin	69.9%	57.1%	-89.0%	103.9%	-52.4%	48.8%	10.9%	-107.2%	100.5%	-339.2%	62.9%	51.3%
Free cash flow margin	9.9%	10.2%	13.2%	17.2%	13.7%	10.9%	16.3%	12.2%	19.0%	8.7%	4.8%	5.7%
Current ratio	3.18	3.14	3.21	5.62	5.44	5.12	5.99	6.48	6.14	6.28	6.57	5.83
Debt to equity	0.11	0.11	0.12	0.16	0.18	0.17	0.18	0.18	0.16	0.18	0.13	0.14

Source: XBRL data Bio-Rad Laboratories Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BIO peers

Company	Revenue	Growth	Net income	Net margin	Market cap
BIO	$2.59B	+1.4%	$1.02B	39.5%	$10.44B
AAgilent Technologies Inc.	$7.37B	+8.6%	$1.44B	19.5%	$50.80B
WATWaters Corporation	$4.64B	+52.5%	$166.14M	3.6%	$46.83B
MTDMettler-Toledo International Inc.	$4.20B	+6.5%	$934.07M	22.2%	$35.31B
RVTYRevvity Inc.	$2.91B	+4.1%	$237.55M	8.2%	$17.93B
AVTRAvantor Inc.	$6.64B	+0.9%	$337.20M	5.1%	$10.78B
BRKRBruker Corporation	$3.51B	+2.2%	-$123.40M	-3.5%	$10.16B
TXG10x Genomics Inc.	$618.58M	-3.6%	-$67.08M	-10.8%	$8.48B

BIO FAQ

9 questions

What is BIO revenue?
Bio-Rad Laboratories Inc. (BIO) reported $2.59B of revenue for the twelve months ended Sep 30, 2026. That is up 1.4% from the year before. Revenue for fiscal 2025 was $2.58B.
Is BIO profitable?
Yes. Bio-Rad Laboratories Inc. earned $1.02B in net income for the twelve months ended Sep 30, 2026, a net margin of 39.5%.
How much cash and debt does BIO have?
Bio-Rad Laboratories Inc. reported $465.30M in cash and cash equivalents and $803.10M of debt on its most recent balance sheet in SEC filings.
How fast is BIO revenue growing?
Bio-Rad Laboratories Inc.'s revenue changed +0.7% in fiscal 2025, to $2.58B. Its compound annual growth rate was +0.3% over 5 years and +2.5% over 10 years.
What is BIO gross margin?
Bio-Rad Laboratories Inc.'s gross profit was $1.33B on $2.59B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 51.3%.
What is BIO free cash flow?
Bio-Rad Laboratories Inc. generated $329.10M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $468.10M less capital expenditures.
What is BIO earnings per share?
Diluted earnings per share were $37.91 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did BIO last report financial results?
The latest statements here come from Bio-Rad Laboratories Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
Where does this BIO financial data come from?
Quantisnow builds these statements from the structured XBRL data Bio-Rad Laboratories Inc. files with the SEC. It is provided for information only and is not investment advice.